Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 8, 2016, Pages 2212-2217

  Camporez, João Paulo G ^a   Petersen, Max C ^a   Abudukadier, Abulizi ^a   Moreira, Gabriela V ^a   Jurczak, Michael J ^b   Friedman, Glenn ^c   Haqq, Christopher M ^c   Petersen, Kitt Falk ^a   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Atara Biotherapeutics   (United States)

Author keywords

Aging; Insulin resistance; Muscle mass; Myostatin; Sarcopenia

Indexed keywords

ATA 842; MONOCLONAL ANTIBODY; MYOSTATIN; UNCLASSIFIED DRUG; MSTN PROTEIN, HUMAN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENERGY EXPENDITURE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; SARCOPENIA; SKELETAL MUSCLE; AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; ENERGY METABOLISM; HUMAN; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; HUMANS; INSULIN RESISTANCE; MALE; MICE; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYOSTATIN; SARCOPENIA;

EID: 84959378307     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1525795113     Document Type: Article

References (37)

1. Baumgartner RN, et al. (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755-763.
2. Burton LA, Sumukadas D (2010) Optimal management of sarcopenia. Clin Interv Aging 5:217-228.
3. Janssen I (2011) The epidemiology of sarcopenia. Clin Geriatr Med 27(3):355-363.
4. Greenlund LJ, Nair KS (2003) Sarcopenia-consequences, mechanisms, and potential therapies. Mech Ageing Dev 124(3):287-299.
5. Bevier WC, et al. (1989) Relationship of body composition, muscle strength, and aerobic capacity to bone mineral density in older men and women. J Bone Miner Res 4(3):421-432.
6. Piers LS, Soares MJ, McCormack LM, O'Dea K (1998) Is there evidence for an age-related reduction in metabolic rate? J Appl Physiol (1985) 85(6):2196-2204.
7. Forbes GB (1999) Longitudinal changes in adult fat-free mass: Influence of body weight. Am J Clin Nutr 70(6):1025-1031.
8. Ryan AS (2000) Insulin resistance with aging: Effects of diet and exercise. Sports Med 30(5):327-346.
9. Avignon A, Radauceanu A, Monnier L (1997) Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20(12):1822-1826.
10. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R (2004) The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 52(1):80-85.
11. McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387(6628):83-90.
12. Rodriguez J, et al. (2014) Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci 71(22):4361-4371.
13. Zimmers TA, et al. (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296(5572):1486-1488.
14. Han HQ, Zhou X, Mitch WE, Goldberg AL (2013) Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential. Int J Biochem Cell Biol 45(10):2333-2347.
15. Izumiya Y, et al. (2008) Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 7(2):159-172.
16. McPherron AC, Lee SJ (2002) Suppression of body fat accumulation in myostatindeficient mice. J Clin Invest 109(5):595-601.
17. Choi SJ, et al. (2011) Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice. Am J Physiol Endocrinol Metab 300(6): E1031-E1037.
18. Camporez JP, et al. (2013) Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154(9):3099-3109.
19. Camporez JP, et al. (2015) ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. J Lipid Res 56(3):526-536.
20. Mosher DS, et al. (2007) A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 3(5):e79.
21. Clop A, et al. (2006) A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38(7):813-818.
22. Schuelke M, et al. (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350(26):2682-2688.
23. Grobet L, et al. (2003) Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene. Genesis 35(4):227-238.
24. Whittemore LA, et al. (2003) Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300(4):965-971.
25. Nakatani M, et al. (2008) Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 22(2):477-487.
26. Haidet AM, et al. (2008) Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 105(11):4318-4322.
27. LeBrasseur NK, et al. (2009) Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 64(9):940-948.
28. Murphy KT, et al. (2010) Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J 24(11):4433-4442.
29. Bernardo BL, et al. (2010) Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulinresistant mice. PLoS One 5(6):e11307.
30. Guo T, et al. (2009) Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One 4(3):e4937.
31. Zhao B, Wall RJ, Yang J (2005) Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun 337(1):248-255.
32. Guo T, et al. (2012) Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes 61(10):2414-2423.
33. Petersen KF, et al. (2003) Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science 300(5622):1140-1142.
34. Kirkman MS, et al. (2012) Diabetes in older adults. Diabetes Care 35(12):2650-2664.
35. Dyle MC, et al. (2014) Systems-based discovery of tomatidine as a natural small molecule inhibitor of skeletal muscle atrophy. J Biol Chem 289(21):14913-14924.
36. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226(1):497-509.
37. Camporez JP, et al. (2013) Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology 154(3):1021-1028.